Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
SYX-1042 by Eli Lilly and Co for Inflammation: Likelihood of Approval
SYX-1042 is under clinical development by Eli Lilly and Co and currently in Phase I for Inflammation. According to GlobalData,...
Data Insights
SYX-1042 by Eli Lilly and Co for Autoimmune Disorders: Likelihood of Approval
SYX-1042 is under clinical development by Eli Lilly and Co and currently in Phase I for Autoimmune Disorders. According to...